All stock lists
Novartis AG (New York Stock Exchange:NVS)
CH · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - General
153.81+2.69 (+1.78%)
Insider Score
––Not scored
NVS Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
NVS analyst forecast
NVS analyst consensus
Hold1 ratings
Buy 0 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
NVS 12-month price target
$156.00+1.4% upsideaverage of 1 firm
$156.00High
$156.00Low
Best analysts covering NVS
No firm covering NVS has enough calls with a finished 1Y holding period to rank yet.
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
NVS analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| Morgan Stanley | — | $156.00 | +10.8% | — | 2026-10-06 | |
| — | HSBC | Hold | — | — | Upgraded | 2026-09-10 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-03-26 |
| — | Barclays | Equal Weight | — | — | Upgraded | 2026-01-06 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2025-12-08 |
| — | Goldman Sachs | Sell | — | — | Downgraded | 2025-09-12 |
| — | UBS | Neutral | — | — | Downgraded | 2025-02-13 |
| — | Erste Group | Hold | — | — | Downgraded | 2024-11-19 |
| — | BMO Capital | Market Perform | — | — | Reiterated | 2024-10-30 |
| — | B of A Securities | Neutral | — | — | Downgraded | 2024-09-11 |
| — | Goldman Sachs | Neutral | — | — | Downgraded | 2024-09-05 |
| — | Jefferies | Hold | — | — | Downgraded | 2024-09-03 |
| — | Jefferies | Buy | — | — | Reiterated | 2024-07-02 |
| — | BMO Capital | Market Perform | — | — | Reiterated | 2024-04-24 |
| — | Morgan Stanley | Equal Weight | — | — | Upgraded | 2023-09-25 |
| — | Wolfe Research | Peer Perform | — | — | Downgraded | 2022-05-09 |
| — | Exane BNP Paribas | Neutral | — | — | Downgraded | 2021-12-06 |
| — | Bryan Garnier | Neutral | — | — | Downgraded | 2021-12-03 |
| — | Deutsche Bank | Sell | — | — | Downgraded | 2021-09-20 |
| — | Argus Research | Hold | — | — | Downgraded | 2021-03-10 |
| — | Cowen & Co. | Market Perform | — | — | Downgraded | 2021-02-01 |
| — | Morgan Stanley | Overweight | — | — | Upgraded | 2020-09-01 |
| — | Guggenheim Securities | Neutral | — | — | Downgraded | 2020-02-25 |
| — | Guggenheim | Neutral | — | — | Downgraded | 2020-02-25 |
| — | Guggenheim | Buy | — | — | Upgraded | 2019-04-25 |
| — | Morgan Stanley | Underweight | — | — | Downgraded | 2019-04-10 |
| — | Cowen & Co. | Outperform | — | — | Upgraded | 2018-11-26 |
| — | Goldman Sachs | Conviction Buy | — | — | Upgraded | 2018-11-19 |
| — | Citigroup | Buy | — | — | Upgraded | 2018-09-11 |
| — | B of A Securities | Buy | — | — | Upgraded | 2018-09-10 |
| — | Bank of America | Buy | — | — | Upgraded | 2018-09-10 |
| — | Barclays | Equal Weight | — | — | Upgraded | 2018-07-19 |
| — | HSBC | Hold | — | — | Downgraded | 2018-05-29 |
| — | Credit Suisse | Neutral | — | — | Upgraded | 2018-05-25 |
| — | Argus | Buy | — | — | Upgraded | 2018-05-05 |
| — | Leerink Swann | Market Perform | — | — | Reiterated | 2018-01-25 |
| — | Barclays | Underweight | — | — | Downgraded | 2017-10-25 |
| — | Leerink Swann | Market Perform | — | — | Reiterated | 2017-10-23 |
| — | Morgan Stanley | Overweight | — | — | Upgraded | 2017-07-26 |
| — | Credit Suisse | Underperform | — | — | Downgraded | 2017-07-05 |
| — | Cowen & Co. | Market Perform | — | — | Downgraded | 2017-04-05 |
| — | Credit Suisse | Neutral | — | — | Downgraded | 2017-01-11 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2017-01-03 |
| — | Argus Research | Buy | — | — | Upgraded | 2016-11-10 |
| — | Argus | Buy | — | — | Upgraded | 2016-11-10 |
| — | Morgan Stanley | Underperform | — | — | Downgraded | 2016-04-12 |
| — | UBS | Neutral | — | — | Downgraded | 2016-04-01 |
| — | Citigroup | Neutral | — | — | Downgraded | 2016-03-29 |
| — | Leerink Swann | Market Perform | — | — | Downgraded | 2016-03-23 |
| — | Leerink Swann | Outperform | — | — | Reiterated | 2015-07-27 |
| — | Bryan Garnier | Buy | — | — | Upgraded | 2015-06-22 |
| — | Natixis | Buy | — | — | Upgraded | 2015-03-04 |
| — | Cowen & Co. | Outperform | — | — | Upgraded | 2015-01-05 |
| — | Morgan Stanley | Equal Weight | — | — | Upgraded | 2014-12-02 |
| — | Jefferies | Buy | — | — | Upgraded | 2014-05-02 |
| — | Natixis | Neutral | — | — | Downgraded | 2014-04-24 |
| — | Jefferies | Hold | — | — | Downgraded | 2014-01-08 |
| — | Natixis | Buy | — | — | Upgraded | 2013-11-25 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2013-10-08 |
| — | Barclays | Underweight | — | — | Downgraded | 2013-09-16 |
NVS earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-04 | 1.99 | 2.03 | $13.70B | $13.34B |
| 2026-04-28 | 2.11 | 1.99 | $13.44B | $13.11B |
| 2026-07-21 | 2.17 | 2.41 | $14.07B | $14.41B |
| 2026-10-27 | 2.25 | 0.00 | $14.53B | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.